Climb Bio Earnings Call Transcripts
Fiscal Year 2026
-
A year of foundational execution sets up multiple data readouts in 2026 for two lead antibody programs targeting B-cell mediated diseases. Key differentiators include broader B-cell targeting, subcutaneous formulations, and a novel APRIL-only antibody, with strong financial runway and ongoing business development focus.
-
The company is advancing two antibody assets, budoprutug (anti-CD19) and CLYM116 (anti-APRIL), targeting immune-mediated diseases with multiple clinical readouts expected this year. Budoprutug has shown durable remissions in PMN, while CLYM116 demonstrates superior preclinical efficacy in IgAN.
-
Multiple clinical readouts are expected in 2024 for two differentiated antibody programs targeting autoimmune diseases, with pivotal studies planned for PMN and IgAN. The company is well-funded into 2028 and is exploring further indication expansion for both assets.
Fiscal Year 2025
-
Multiple data readouts for two monoclonal antibodies are expected in 2026, targeting PMN, ITP, SLE, and IgA nephropathy. Dose optimization and subQ formulations are key strategies, with a strong financial runway through 2027.
-
Climb 116, a next-generation anti-APRIL sweeper antibody, is advancing toward clinical trials for IgA nephropathy, aiming for best-in-class efficacy with deeper and more durable IgA suppression and less frequent dosing. Preclinical data show superior PK/PD versus first-generation agents, and global development is supported by a partnership with Mabwell.
-
The company is advancing monoclonal antibody programs for B-cell mediated diseases, with Budoprutug and CLYM116 targeting CD19 and APRIL, respectively. Multiple clinical trials are underway, with a cash runway through 2027 and key data readouts expected in 2026 and later this year.
-
Focused on monoclonal antibodies for B-cell-mediated diseases, the company advances Budo (CD19-targeted) and CLYM116 (anti-APRO) with a data-driven, indication-bucketed strategy. Early clinical data show strong efficacy in PMN, with multiple studies ongoing and key data readouts expected in the next 12–18 months.
-
The company is advancing two main assets for immune-mediated diseases, focusing on CD19-targeted and anti-APRIL monoclonal antibodies. Early clinical data show strong efficacy and safety, with biomarker-driven strategies guiding development. Key priorities include execution, differentiation, and strategic indication selection.
-
Focused on immune-mediated diseases, the company is advancing two B-cell-targeting assets—Budo (CD19 MAB) and CLYM116 (APRIL sweeper MAB)—with strong early clinical data in PMN and upcoming studies in ITP and SLE. Well-funded through 2027, key 2024 milestones include multiple trial initiations and preclinical data updates.
-
The company is advancing two key monoclonal antibody assets for immune-mediated diseases, with Budo showing strong early efficacy in PMN and plans for further studies in ITP and SLE. CLYM116, a differentiated anti-APRIL antibody, is moving toward clinical trials. Both assets are supported by robust financial resources and strategic IP protection.
-
Focused on immune-mediated diseases, the company advances two antibody programs targeting B-cell and plasma cell pathways. Early clinical data show strong efficacy and safety, with multiple trials and key data readouts expected through 2025.
-
The company is advancing a pipeline of immune-mediated disease therapies, led by Budo, a potent CD19 antibody targeting PMN, ITP, and SLE, with early data showing strong efficacy and safety. CLYM116, an APRIL-targeted antibody for IgA nephropathy, is also progressing, with key data and clinical milestones expected this year.